Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Tiny particles could make a powerful COVID vaccine

Colorized scanning electron micrograph of a cell infected with SARS-CoV-2 virus particles

A human cell infected with SARS-CoV-2 particles (purple; artificially coloured), which can be fended off by a vaccine based on the virus’s receptor binding domain. Credit: NIAID (CC BY 2.0)

An experimental COVID-19 vaccine that uses an atypical ingredient to stimulate an immune response shows promise against several variants of the coronavirus — at least in monkeys.

The mRNA COVID-19 vaccines stimulate the immune system by exposing it to the SARS-CoV-2 protein, called spike, that enables the virus to latch on to cells. David Veesler and Neil King at the University of Washington in Seattle and their colleagues made a vaccine that relies instead on a spike fragment called the receptor binding domain (RBD). They injected monkeys with nanometre-scale particles studded with dozens of RBDs and found that the vaccine generated virus-blocking ‘neutralizing’ antibodies against the Alpha, Beta and Gamma variants, and related animal coronaviruses. This vaccine is currently in phase III clinical trials.

The team also tested nanoparticle vaccines containing RBDs from a mix of sarbecoviruses, a family of coronaviruses that includes SARS-CoV-2. In mice, these vaccines triggered production of neutralizing antibodies against multiple coronaviruses.

These findings pave the way for a pan-sarbecovirus vaccine that could protect against SARS-CoV-2 variants and sarbecoviruses that jump from animals to humans in the future.

Nature 597, 596 (2021)




Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links